Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 111Terminated 34Unknown 11Withdrawn 8Active not recruiting 2Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Patient Compliance 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × Lapatinib × Clear all
NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

NCT00999804 2025-03-12

HELEX

Baylor Breast Care Center

Phase 2 Active not recruiting
128 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡